Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New EU Consortium Focused on Discovery and Development of Novel Eye Therapeutics

Published: Monday, October 14, 2013
Last Updated: Monday, October 14, 2013
Bookmark and Share
Consortium supported by EU Seventh Framework Programme.

KalVista Pharmaceuticals is joining a group of academic and industry researchers to undertake a project known as ‘3D-NET’ (‘Drug Discovery and Development of Novel Eye Therapeutics’).

The four-year project seeks to enable the development of new drugs for the treatment of ocular disease associated with inflammation, neovascularisation, edema and degeneration, through the complementary capabilities of the partners.

The project will be funded through a €1.66 million Marie Curie Industry-Academia Pathways and Partnerships (IAPP) grant award from the EU Seventh Framework Programme (612218/3D-NET).

The consortium partners, in addition to KalVista, include leading researchers in front- and back-of-the-eye diseases, ocular disease models and synthetic chemistry at University College Dublin (Ireland), Universidad de Valladolid (Spain), RenaSci Ltd (Nottingham, UK) and Gadea Grupo Farmacéutico (Spain).

KalVista brings expertise in ocular diseases resulting from diabetes, such as diabetic macular edema, an extensive library of novel compounds already screened for activity in the eye, and proven capabilities in the development of drugs from target identification through to in vitro pharmacology and safety.

“We are delighted to be part of this EU project. The consortium brings a unique combination of skills and opportunities to overcome barriers to ocular drug discovery and development and advance new therapies for a range of eye diseases,” commented Andrew Crockett, KalVista CEO.

Crockett continued, “In addition, this project will provide KalVista with access to new ophthalmology projects and dovetails nicely with our internal programmes focused on intravitreal and oral plasma kallikrein inhibitors for DME. The intravitreal programme is advancing rapidly to the first in human trial, expected to start in early 2014, and we continue to progress our programme focused on novel oral drugs for DME.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

KalVista Announces Start of Clinical Development for Novel Treatment for DME
Phase I trial of plasma kallikrein inhibitor to be conducted in the US.
Thursday, August 21, 2014
KalVista Wins £2.4m Biomedical Catalyst Grant
Grant to further develop oral plasma kallikrein inhibitors as a treatment for diabetic macular edema.
Tuesday, November 06, 2012
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!